p53、c-erbB-2及血管内皮生长因子蛋白表达对非小细胞肺癌辅助化疗的临床预测

Clinical prediction of p53,c-erbB-2 and vascular endothelial growth factor protein expression in adjuvant chemotherapy for non-small cell lung cancer

目的:研究检测p53、c-erbB-2及血管内皮生长因子(VEGF)蛋白表达水平对非小细胞肺癌(NSCLC)辅助化疗的预后判断情况。方法:临床纳入84例我院2013年8月至2015年8月期间收治的NSCLC患者作为研究对象,根据治疗方法不同分为单纯手术组和辅助化疗组各42例。对两组患者术后病理切片标本中p53、c-erbB-2以及VEGF蛋白水平进行检测,观察三种指标的表达情况,分析其临床预测能力。结果:两组患者p53、c-erbB-2以及VEGF蛋白水平表达情况差异无统计学意义(P>0.05)。p53、c-erbB-2以及VEGF表达阴性的患者1年生存率明显高于表达阳性的患者(均P<0.05)。结论:NSCLC患者检测p53、c-erbB-2以及VEGF蛋白水平对患者手术或辅助化疗后的疗效具有一定预测作用,具有重要临床价值。

Objective： To investigate the prognostic evaluation of p53,c-erbB-2 and vascular endothelial growth factor（ VEGF） protein expression levels in adjuvant chemotherapy for non-small cell lung cancer（ NSCLC）.Methods： Eighty-four NSCLC patients,who were hospitalized in our hospital between August 2013 and August 2015,were included as the subjects in the study. According to different treatment methods,all patients were divided into the simple operation group and adjuvant chemotherapy group（ n = 42 each）. The protein levels of p53,c-erbB-2 and VEGF in the pathological specimens of the two groups were examined,and the expression of three indexes were determined.The clinical prediction was analyzed.Results： There were no statistically significant differences in the expression of p53,c-erbB-2 and VEGF between the two groups（ P〈0.05）. The 1-year survival rate in patients with negative expression of p53,c-erbB-2 and VEGF was significantly higher than that in patients with positive expression（ all P〈0.05）.Conclusion： The determination of p53,c-erbB-2 and VEGF protein levels in NSCLC patients is predictive for the effect of operation or adjuvant chemotherapy,which shows significantly clinical value.